Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CureVac N.V (CVAC) Common Equity: 2019-2025

Historic Common Equity for CureVac N.V (CVAC) over the last 4 years, with Jun 2025 value amounting to $663.7 million.

  • CureVac N.V's Common Equity rose 63.69% to $663.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $663.7 million, marking a year-over-year increase of 63.69%. This contributed to the annual value of $744.4 million for FY2024, which is 33.84% up from last year.
  • Latest data reveals that CureVac N.V reported Common Equity of $663.7 million as of Q2 2025, which was down 2.43% from $680.2 million recorded in Q1 2025.
  • CureVac N.V's Common Equity's 5-year high stood at $1.0 billion during Q2 2021, with a 5-year trough of $405.5 million in Q2 2024.
  • Moreover, its 3-year median value for Common Equity was $672.0 million (2025), whereas its average is $646.0 million.
  • In the last 5 years, CureVac N.V's Common Equity soared by 92,100.27% in 2021 and then crashed by 42.63% in 2024.
  • Quarterly analysis of 5 years shows CureVac N.V's Common Equity stood at $787.6 million in 2021, then slumped by 30.92% to $544.0 million in 2022, then increased by 2.23% to $556.2 million in 2023, then surged by 33.84% to $744.4 million in 2024, then surged by 63.69% to $663.7 million in 2025.
  • Its Common Equity was $663.7 million in Q2 2025, compared to $680.2 million in Q1 2025 and $744.4 million in Q4 2024.